• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Atlantic International Corp.

    8/15/25 4:05:06 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ATLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    Atlantic International Corp.

    (Name of Issuer)


    Common Stock, Par Value $0.00001 per share

    (Title of Class of Securities)


    048592109

    (CUSIP Number)


    Elliot H. Lutzker,
    Davidoff Hutcher & Citron LLP, 605 Third Avenue
    New York, NY, 10158
    212-557-7200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    08/11/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    048592109


    1 Name of reporting person

    Jeffrey Jagid
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    7,221,025.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    7,221,025.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    7,221,025.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.6 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, Par Value $0.00001 per share
    (b)Name of Issuer:

    Atlantic International Corp.
    (c)Address of Issuer's Principal Executive Offices:

    270 Sylvan Avenue, Suite 2230, Englewood Cliffs, NEW JERSEY , 07632.
    Item 2.Identity and Background
    (a)
    Jeffrey Jagid
    (b)
    270 Sylvan Avenue, Suite 2230, Englewood Cliffs, New Jersey 07632.
    (c)
    CEO and Director, Atlantic International Corp., 270 Sylvan Avenue, Suite 2230, Englewood Cliffs, New Jersey 07632.
    (d)
    No criminal proceedings to be disclosed
    (e)
    No civil proceedings to be disclosed
    (f)
    United States
    Item 3.Source and Amount of Funds or Other Consideration
     
    See Item 5(c) below.
    Item 4.Purpose of Transaction
     
    There are no plans or proposals which the reporting person has which may result in any of the matters listed.
    Item 5.Interest in Securities of the Issuer
    (a)
    7,221,025 (11.6%) shares based on 58,375,488 shares issued and outstanding as of August 8, 2025.
    (b)
    Sole voting power and disposition power - 7,221,025 shares.
    (c)
    Pursuant to the terms and conditions of an Executive Employment Agreement dated June 18, 2024, by and between Mr. Jagid and Atlantic International Corp., Mr. Jagid received 3,735,169 shares of Common Stock of the Issuer, upon the June 18, 2024 merger with SeqLL Inc., which changed its name to Atlantic International Corp. The 2,885,856 shares of Common Stock issued on January 2, 2025 pursuant to restricted stock units ("RSUs") under his employment agreement were issued in error and returned to the Issuer. In addition to the previously granted 2,885,856 RSUs, an additional 1,000,000 restricted shares were awarded by the Board of Directors on August 11, 2025, as the Company had agreed to review the equity compensation for senior management within one year of the June 18, 2024 closing date of the acquisition of Lyneer Investments LLC. On August 11, 2025, Mr. Jagid gifted 200,000 shares of common stock to each of his two brothers Jonathan Jagid and Joshua Jagid in transactions that were exempt from regulation under Section 16(b).
    (d)
    No person has the right to receive, or the power to direct the receipt of dividends from, or proceeds from, the sale of such securities.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    None
    Item 7.Material to be Filed as Exhibits.
     
    None

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Jeffrey Jagid
     
    Signature:/s/ Jeffrey Jagid
    Name/Title:Jeffrey Jagid/Chief Executive Officer and Director
    Date:08/15/2025
    Get the next $ATLN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATLN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATLN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Atlantic International Corp.

    SCHEDULE 13D/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Subject)

    8/15/25 4:05:06 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form RW filed by Atlantic International Corp.

    RW - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    7/14/25 4:05:04 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 424B3 filed by Atlantic International Corp.

    424B3 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Filer)

    7/8/25 4:31:45 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Broderick Christopher bought $58 worth of shares (577,171 units at $0.00), increasing direct ownership by 40% to 2,004,237 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:11:34 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Executive Officer Jagid Jeffrey M bought $289 worth of shares (2,885,856 units at $0.00), increasing direct ownership by 340% to 3,735,169 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:04:40 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: General Counsel Tenore Michael bought $58 worth of shares (577,171 units at $0.00), increasing direct ownership by 136% to 1,001,634 units (SEC Form 4)

    4/A - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    6/25/25 5:02:59 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atlantic International Corp. to Present at the 2025 Gateway Conference on September 4

    ENGLEWOOD CLIFFS, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a rapidly expanding provider of workforce solutions and outsourced services, today announced that its CEO will present at the 2025 Annual Gateway Conference, one of the nation's premier investor events connecting high-growth companies with institutional investors, analysts, and capital markets professionals. The conference will take place September 4–5, 2025, at the Four Seasons Hotel in San Francisco, CA. Jeffrey Jagid, Atlantic International Corp.'s CEO, is scheduled to present on Thursday, September 4 at 9:00 a.m. Pacific Time (PT). The presentation will be webcast live and ava

    8/18/25 7:00:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Atlantic International Corp. Reports Strong Operational Improvements in Second Quarter 2025

    ENGLEWOOD CLIFFS, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a leading strategic staffing, outsourced services, and workforce solutions company, today announced financial results for the second quarter ended June 30, 2025, demonstrating significant operational improvements and a strengthened financial position. Second Quarter 2025 Highlights: Net loss narrowed by 81% to $10.7 million (or $0.20 per share), compared to a net loss of $54.9 million (or $1.96 per share) in Q2 2024Service revenue was $102.9 million, with permanent placement services up 17% year-over-year.Gross profit margin improved to 11.1%, reflecting pricing discipline and efficiency

    8/14/25 7:00:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gateway Group Announces Preliminary Sponsors and Presenting Companies for 2025 Gateway Conference

    NEWPORT BEACH, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Gateway Group ("Gateway"), a leading financial communications and digital media advisory firm, today announced the initial sponsors and presenting companies confirmed for its annual Gateway Conference taking place at the Four Seasons Hotel in San Francisco on September 3rd and 4th. The conference is expected to host more than 300 institutional investors and analysts for two days of company presentations and curated one-on-one meetings with executives from high-growth public and private companies across the tech, AI, cleantech, consumer, financial services, and industrials sectors. "We appreciate the strong support from our sponsors

    7/30/25 8:30:00 AM ET
    $ACNT
    $AIRG
    $AKA
    Steel/Iron Ore
    Industrials
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ATLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Broderick Christopher

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    8/15/25 5:10:50 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by General Counsel Tenore Michael

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    8/13/25 4:46:32 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Jagid Jeffrey M gifted 400,000 shares, decreasing direct ownership by 11% to 3,335,169 units (SEC Form 4)

    4 - ATLANTIC INTERNATIONAL CORP. (0001605888) (Issuer)

    8/13/25 4:45:41 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Financials

    Live finance-specific insights

    View All

    Atlantic International Corp. Reports Strong 2024 Results with Over $442 Million in Revenue; Over 10% Revenue Growth

    Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under "ATLN" Announces Strategic Developments and Outlook; Targets $1 to $1.5 Billion Revenue from Both Organic Growth and M&A Initiatives in the Next 12 to 18 Months ENGLEWOOD CLIFFS, N.J., March 28, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. ("Atlantic" or the "Company") (NASDAQ:ATLN), a leading provider of strategic staffing, outsourced services and workforce solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2024. Key Financial Highlights: Q4 2024 Revenue: Revenue for the fourth quarter was $129.5 million, representing an 11.5% increase from $116.

    3/28/25 7:30:00 AM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATLN
    Leadership Updates

    Live Leadership Updates

    View All

    Atlantic International Corp. Appoints Industry Veteran Matt Evelt as Chief Operating Officer to Lead Global Workforce Solutions Strategy

    ENGLEWOOD CLIFFS, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Atlantic International Corp. (NASDAQ:ATLN), a premier provider of outsourced services, staffing, and workforce solutions, today announced the appointment of Matt Evelt as Chief Operating Officer (COO), effective immediately. Evelt brings more than two decades of leadership experience in workforce strategy, operational transformation, and international expansion. In his new role, he will oversee global operations, drive efficiency, and help scale Atlantic International's delivery of innovative, client-focused staffing and workforce solutions. Evelt most recently served as President – Americas at Airswift, where he successfully led

    6/2/25 1:05:49 PM ET
    $ATLN
    Biotechnology: Laboratory Analytical Instruments
    Industrials